Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Deffered Revenue: 2014-2023

Historic Non-Current Deffered Revenue for Capricor Therapeutics (CAPR) over the last 4 years, with Sep 2023 value amounting to $953,470.

  • Capricor Therapeutics' Non-Current Deffered Revenue fell 90.32% to $953,470 in Q3 2023 from the same period last year, while for Sep 2023 it was $953,470, marking a year-over-year decrease of 90.32%. This contributed to the annual value of $9.5 million for FY2022, which is N/A change from last year.
  • Latest data reveals that Capricor Therapeutics reported Non-Current Deffered Revenue of $953,470 as of Q3 2023, which was down 70.50% from $3.2 million recorded in Q2 2023.
  • Over the past 5 years, Capricor Therapeutics' Non-Current Deffered Revenue peaked at $20.3 million during Q1 2022, and registered a low of $953,470 during Q3 2023.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $9.5 million (2022), whereas its average is $9.1 million.
  • Data for Capricor Therapeutics' Non-Current Deffered Revenue shows a maximum YoY plummeted of 90.32% (in 2023) over the last 5 years.
  • Capricor Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $9.5 million in 2022, then slumped by 90.32% to $953,470 in 2023.
  • Its last three reported values are $953,470 in Q3 2023, $3.2 million for Q2 2023, and $5.4 million during Q1 2023.